According to the Digital Therapeutics Alliance , Digital Therapeutics (DTx) deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes.
DTx products incorporate advanced technology best practices relating to design, clinical validation, usability, and data security. They are validated by regulatory bodies as required to support product claims regarding risk, efficacy, and intended use. Digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.
Digital therapeutics form an independent category of evidence-based products within the broader digital health landscape. Digital therapeutics are distinguished from other digital health categories through their primary function of delivering software-generated therapeutic interventions directly to patients to prevent, manage, or treat a medical disorder or disease.
Access Market Intelligence’s inaugural Digital Therapeutics Insight line focuses on DTx in the commercial insurance market. Our service includes an industry database, landscape and trend reports, custom research, and strategy consulting with an emphasis on market access and reimbursement.
|Application||Type||DTx Company||Partners||End User||Reimbursement|
AMI’s first report in this series: Digital Therapeutics in the Diabetes Market, provides a brief overview of the Diabetes market as well as profiles of the digital therapeutic companies offering products and services in the market. DTx company profiles include: address, website, executive contacts, background, products, partners, end users, and recent activities.
The report also includes brief profiles of the companies partnering with digital therapeutic companies in the diabetes market. Partner profiles include: website, digital executive contacts, background, products/solutions, partners and recent activities.
The Table of Contents include:
Introduction – pg. 4
Diabetes Market Overview – pgs. 5-7
Digital Therapeutic Company Profiles – pgs. 8-55
- Amalgam Rx – pgs. 10-11
- Better Therapeutics – pgs. 12-13
- Blue Mesa Health – pgs. 14-15
- BrightInsight – pgs. 16-17
- Closed Loop Medicine – pgs. 18-19
- DarioHealth – pgs. 20-22
- Glooko Inc. – pgs. 23-25
- Health2Sync – pgs. 26-27
- Lark Health – pgs. 28-29
- Livongo Health – pgs. 30-32
- my mhealth limited – pgs. 33-34
- mySugr GmbH – pgs. 35-36
- Omada Health – pgs. 37-39
- Proteus Digital Health – pgs. 40-41
- Rimidi – pgs. 42-44
- RMDY Health – pgs. 45-46
- Vida Health – 47-48
- Virta Health – pgs. 49-50
- Welldoc – pgs. 51-53
- Wellthy Therapeutics – pgs. 54-55
Partner Company Profiles – pgs. 56-78
- Abbott – pgs. 57-58
- Ascensia Diabetes Care – pgs. 59-61
- CVS Health – pgs. 62-63
- Dance Biopharm Holdings – pg. 64
- Lifescan – pgs. 65-66
- Eli Lilly and Company – pgs. 67-68
- Merck KGaA – pg. 69
- Novo Nordisk – pgs. 70-72
- Roche – pgs. 73-74
- Sanofi – pgs. 75-76
- Samsung Health – pgs. 77-78
- Sources/References – pg. 79